BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

361.65 +3.58 (+1.00%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

October 20, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

October 13, 2025

From BeOne Medicines Ltd.

Via Business Wire

Where BeOne Medicines Stands With Analysts ↗

October 08, 2025

Via Benzinga

Analyst Expectations For BeOne Medicines's Future ↗

September 18, 2025

Via Benzinga

A Glimpse of BeiGene's Earnings Potential ↗

August 07, 2025

Via Benzinga

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

September 07, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

BeiGene's Earnings: A Preview ↗

August 05, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients ↗

August 29, 2025

BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.

Via Benzinga

Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday ↗

August 29, 2025

Via Benzinga

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

August 29, 2025

From BeOne Medicines Ltd.

Via Business Wire

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

August 27, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

August 25, 2025

From BeOne Medicines Ltd.

Via Business Wire

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

August 21, 2025

From BeOne Medicines Ltd.

Via Business Wire

Earnings Scheduled For August 8, 2025 ↗

August 08, 2025

Via Benzinga

BeOne Medicines (ONC) Q2 EPS Soars 924% ↗

August 06, 2025

Via The Motley Fool

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

August 06, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

July 31, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

July 28, 2025

From BeOne Medicines Ltd.

Via Business Wire

Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings) ↗

July 16, 2025

Via Benzinga

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

July 16, 2025

From BeOne Medicines Ltd.

Via Business Wire

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

July 10, 2025

From BeOne Medicines Ltd.

Via Business Wire

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

What 8 Analyst Ratings Have To Say About BeOne Medicines ↗

June 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.